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Abstract
Introduction: Synovial sarcoma of the ovary is a very rare tumor reported only once in the past. It is the second softest tissue mass
after rhabdomyosarcoma in adults but its usual site is extremities not ovary.
Case Presentation: Here we describe a 53-year-old woman with primary synovial sarcoma of the ovary with insufficient treatment
and lung metastasis of the tumor.
Conclusions: Because of harmlessness symptoms, it is usually missed and correct treatment is delayed. When facing this type of
tumor, referring to well-equipped centers with experienced surgeons in this field is recommended for sufficient treatment and best
results.
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1. Introduction
Synovial sarcoma is a well-defined and malignant soft
tissue neoplasm especially in young patients although it
may occur in any age (1). 5% - 10% of soft tissue sarcomas
are synovial sarcomas, which are high-grade tumors rank-
ing second after rhabdomyosarcoma in adolescents and
children (2). Epidemiologically, the overall prevalence has
been reported 7.25 per 100.000 (3). It occurs in women
more than in men (4). Trans location(X; 18), (p11; q11) is
known as the etiology and it is reported that this genetic
abnormality exists approximately in 90% of patients with
the disease. In this translocation, SYT gene on chromo-
some number 18 fuses to either SSX1 or SSX2 on the X chro-
mosome. The name of its tumor never expresses its ori-
gin and it is not supposed to be raised on synovial tissue
of the joints but can occur anywhere in the body. In fact,
the reason of this naming is the similarity between tumor
cells and synoviocytes (4). Histologically, it is divided into
three subtypes: Biphasic, monophasic, and poorly differ-
entiated. Local recurrence and distant metastasis are com-
mon in up to 70%, and there is some evidence of tumor
spreading (5, 6). Given the low incidence and harmless-
ness symptoms, exact diagnosis often is delayed leading
to referring to non-third level hospitals, insufficient treat-
ment, and undesirable results. Our case is one of them.
Meanwhile to our knowledge, our presentation is the sec-
ond case reported.
2. Case Presentation
We describe here a 53-year-old patient who came to our
joint oncology committee at Imam Khomeini hospital affil-
iated to Tehran University of Medical Sciences, Tehran, Iran,
with post-menopausal bleeding. She had undergone left
ovarian cystectomy and right oophorectomy via laparo-
tomy due to a solid mass with 15-centimeter dimensions
3 years earlier in one of the country’s border cities. Her
histopathological diagnosis was synovial sarcoma of the
ovary and left luteal cyst confirmed with a second opin-
ion of another pathologist. Immunohistochemistry stain-
ing included the fallowing markers: positive for CK and
S 100, negative for CD 34, HMB 45, Desmin, and Ki-67. In
fact, the management of the patient was at a setting with
insufficient experience in this field and thus, she did not
have complete surgery following this diagnosis. Of course,
her surgeon stated that according to the history of four
times cesarean sections as well as due to the recent surgery
and the potential risks of complex laparotomy, she was ad-
vised to go to a Referral center, but she refused. Inevitably,
she gave combined regimen of chemotherapy composed
of Mesna+ Adriamycin+ Iphosphamid in five days every
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three weeks for six cycles. At that time, her metastasis
workup was negative. She did not have any symptoms in
her follow-up period for three years until she presented
due to suffering from post-menopausal bleeding. There
was nothing special in her examination except for vagi-
nal atrophy. We performed vaginal sonography, pipelle
biopsy, thoracic and abdominopelvic CT scan with and
without contrast for detection of potential metastasis ac-
cording to her history of ovarian synovial sarcoma. En-
dometrial biopsy was normal. We discovered tree nod-
ules in left lower lobe of the lung from 5 millimeters to
8 millimeters. In the joint committee, a second opinion
of an experienced pathologist was scheduled to confirm
synovial sarcoma and if the diagnosis was the same, com-
plete surgery and chemotherapy would be considered for
the patient. Microscopic examination revealed neoplas-
tic proliferation denoted by sheets and nests and some ar-
rangements of atypical cell with glandular, vesicular struc-
tures and pleomorphic nuclei with foci of necrosis (Figure
1). In immunohistochemistry, staining positivity was seen
in the markers CKAE/AE3, EMA, Vimentin, and Bcl2 while
the following markers showed negative staining: Calre-
tinin, Inhibin, H-Caldesmin, CD10, and Ki 67 was 10% - 15%.
Thus, Biphasic Synovial sarcoma was endorsed. Neverthe-
less, no part of the healthy ovarian tissue was seen. Biopsy
of her lung nodules reveled tumor spreading, too. She un-
derwent complete surgical staging and hysterectomy, uni-
lateral oophorectomy, omentectomy and pelvic and para
aortic lymph nodes dissection. During operation, we did
not detect any structure as right ovarian tissue. This was
because the whole ovarian tissue probably had been tu-
morized and resected 3 years ago. Her post operational pe-
riod was uneventful. In addition, there was no tumoral tis-
sue in all of the specimens in the pathological findings. She
advised to perform 3 - 4 cycles of chemotherapy as neo adju-
vant treatment before lung metastasectomy. However, de-
spite our explanations and insistences, the patient did not
agree and came back to her city. It has been 5 months since
then and in her new CT scan of the chest, her responsible
surgeon reported no change in lung nodules size. She is
asymptomatic now and is under follow up.
3. Discussion
Synovial sarcoma is one of the most common soft tis-
sue sarcomas in adults and approximately 30% of cases oc-
cur in the two first decades of life. The average age at di-
agnosis is 30 years (7), but it can develop at any age. Our
patient was 50 years at the initial diagnosis time. It is
usually presented in lower and upper proximal extremi-
ties but can occur at any location such as stomach, kidney,
Figure 1. Microscopic examination shows neoplastic tissue composed of two cell
populations, spindle cells with long spindle nuclei and eosinophilic cytoplasm and
clusters of epithelioid cells with occasional glandular structures.
uterus, pelvic, and ovary (1, 8-10). Typically, synovial sarco-
mas exist for a long time and are suddenly symptomatic
by rapid growth. Our case had a large ovarian mass that
caused abdominal pain. There is no consensus about prog-
nostic factors but previous studies have reported Bipha-
sic subtype, SYT-SS1 fusion, location in extremities, tumor
size less than 5 centimeters, female gender, age below 50,
and negative surgical margin (11). The presented patient
had only two positive prognostic factors including female
gender and Biphasic pathologic subtype. Nevertheless, she
had almost all of the negative factors mentioned above.
The most site of metastases is lung and it can occur late.
Therefore, long-term surveillance should be considered.
Other common sites are liver and bone, in sequence. Re-
currence has been reported up to 69 months. So, long fol-
low up is recommended to discover local or distant relapse
of the tumor. Rarity of this tumor leads to a challenge in
the management as well as in the treatment that is con-
troversial. Radical surgery followed by radiotherapy and
chemotherapy has been described (12). In our case, it was
necessary to complete surgical staging before chemother-
apy but she refused the correct treatment option. We com-
pleted the surgery and according to thorax surgeons’ rec-
ommendation stating that neo adjuvant chemotherapy
could be helpful, we advised her to receive neo adjuvant.
She had a special character not to accept surgeon’s opin-
ion, leading to incomplete treatment in this stage similar
to the previous steps, as described before. In lung involve-
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ment of sarcoma, metastasectomy even if nodules are nu-
merous is done that may increase overall survival in some
patients (13). Of course, this option was not carried out for
her. To determine whether the primary origin of the tu-
mor is ovary, it is better to detect at least a small part of the
normal ovarian tissue. Although we did not find it, there
was no remnant tissue neither in follow-up imaging after
the first surgery nor in pathological examination of second
radical surgery. Therefore, it was a primary ovarian syn-
ovial sarcoma that based on our knowledge is reported for
the second time.
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